Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

•The PACIFIC trial established durvalumab after CRT as standard of care for unresectable, stage III NSCLC.•The optimum multimodal treatment strategy for patients with potentially resectable, stage IIIA-N2 NSCLC is unknown.•Survival benefit with durvalumab was observed in patients with stage IIIA-N2, unresectable NSCLC in this post hoc analysis.•Durvalumab after CRT also exhibited a manageable safety profile in this subpopulation from PACIFIC.•Studies of surgical vs. non-surgical strategies are needed to establish the best approach for potentially operable patients.